Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 12 min 9 sec ago

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection

Wed, 14/11/2018 - 16:00
HOUSTON--(BUSINESS WIRE)--#celltherapy--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (

Generex Revises Record & Payment Dates for 20:1 Stock Dividend

Wed, 14/11/2018 - 12:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has revised the record and payment dates for the previously announced 20:1 common stock dividend. The Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s 20:1 common stock dividend will now be Tuesday, November 20, 2018. The dividend Payment Date will be Friday, No

TeamBest Companies Enters Agreement to Acquire ABT Molecular Imaging, Inc. and Announces Creation of Best ABT, Inc.

Mon, 12/11/2018 - 16:00
WASHINGTON & KNOXVILLE, Tenn. & VANCOUVER, British Columbia--(BUSINESS WIRE)--#ABT--TeamBest Companies enters agreement to acquire ABT Molecular Imaging, Inc. and announces creation of Best ABT, Inc.

Devonian Health Group Announces the Recognition of Sybil Dahan, President of Altius Healthcare, as Inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.

Mon, 12/11/2018 - 11:00
QUEBEC--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announces the recognition of Sybil Dahan, President of Altius Healthcare - commercial division of Devonian - as an inductee into the 2018 Canadian Healthcare Marketing Hall of Fame. The 2018 Annual Canadian Healthcare Hall of Fame Inductees, inc

Mperia Therapeutics Appoints Paul Chipperton as President and CEO

Fri, 09/11/2018 - 08:00
MONTREAL--(BUSINESS WIRE)--#amorchem--Mperia Therapeutics appoints Payl Chipperton as President and CEO

Aurinia to Participate in November Investor Conferences

Fri, 09/11/2018 - 08:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences. Wednesday, November 14, 2018, Aurinia will present a company overview at the Jefferies 2018 London Healthcare Conference in London, UK at 10:00am GMT. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay

Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

Thu, 08/11/2018 - 17:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. “We achieved a significant milestone in September with the completion of enrollment for the AURORA Phase III trial ahead of schedule. Our target enrollment of 324 patients was surpassed due to high patient demand with 358

Zymeworks to Present at Upcoming Investor Conferences

Wed, 07/11/2018 - 17:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England. The Company will provide a corporate update at the Stifel Healthcare Conference

Titan Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

Wed, 07/11/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern ti

Zymeworks Reports Financial Results for the Third Quarter of 2018

Tue, 06/11/2018 - 17:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “We continue to expand our business with our seventh pharmaceutical partner, LEO Pharma, recently entering into a strategic collaboration with Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “Importantly, this deal represents the evol

Ag-West Bio Welcomes Two New Board Members

Tue, 06/11/2018 - 10:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Ag-West Bio welcomes Shawn Gibson and Danya Kordan to its board of directors. Shawn Gibson is executive director at the Agriculture Research Branch, Saskatchewan Ministry of Agriculture. Danya Kordan is Director of Research Institutes and Clusters at Innovation Saskatchewan. As the sole ‘Class A member’ of Ag-West Bio, the Government of Saskatchewan (represented by Saskatchewan Ministry of Agriculture) is entitled to elect two directors to Ag-West Bio’s

Abzena Announces 20m$ Investment into Expansion of Integrated Biotherapeutics Offering (Biologics Drug Substance and ADC) and Makes Key Executive Appointment

Tue, 06/11/2018 - 08:00
SAN DIEGO & BRISTOL, Pa. & CAMBRIDGE, England--(BUSINESS WIRE)--Increased biologics manufacturing capacity in San Diego, cell line development capabilities in Cambridge and synthetic chemistry services in Bristol.

Acerus Reports Third Quarter 2018 Financial Results

Tue, 06/11/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars. Recent Operational and Financial Highlights Increased product revenue by 16% to $1.6 million versus $1.4 million in the same three-month period in the prior year; Closed $11 million term loan credit facility with SWK Funding LLC (“SWK”); Repaid all

Amorchem Selected for Investment by the Venture Capital Catalyst Initiative

Tue, 06/11/2018 - 08:00
MONTREAL--(BUSINESS WIRE)--#amorchem--November 6th, 2018, AmorChem is proud to be amongst the successful applicants of the Venture Capital Catalyst Initiative (“VCCI”) Stream II, announced yesterday in Montreal by the Honourable Mary Ng, federal Minister of Small Business and Export Promotion, joined by Richard Hébert, Parliamentary Secretary to the Minister of Small Business and Export Promotion. AmorChem was built through the vision and leadership of its two founders, Elizabeth Douville and Inès Holzbau

Novanta Announces Financial Results for the Third Quarter 2018

Tue, 06/11/2018 - 07:00
BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2018.     Financial Highlights Three Months Ended (In millions, except per share amounts) September 28,     September 29, 2018 2017 GAAP Revenue $ 160.8 $ 146.3 Operating Income $ 21.0 $ 12.4 Net Income Attributable to Novanta Inc. $ 14.6 $ 7.5 Diluted EPS $ 0.60 $ (0.00 ) Non

Generex Biotechnology Finalizes Acquisition of Remaining Veneto Operating Assets

Fri, 02/11/2018 - 10:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has completed the second and final tranche of the acquisition of operating assets from Veneto Holdings, L.L.C. (“Veneto”), a private company, and certain of its affiliated entities (collectively, the “Veneto Group”). The Veneto Group provides specialty pharmacy services and products including surgical products and services, diagnos

SemaThera Board Names Garth Cumberlidge as President & CEO

Thu, 01/11/2018 - 08:00
MONTREAL--(BUSINESS WIRE)--#amorchem--SemaThera Inc., announces today that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retinopathies. Its lead compound, ST-102, is a bispecific recombinant protein trap, binding both VEGF and SEMA3A. “AmorChem is proud to welcome Garth Cumberlidge to the

Nautilus Biosciences Officially Opens Its Expanded UPEI-Based Facility as Croda’s Centre of Innovation for Marine Biotechnology

Wed, 31/10/2018 - 15:00
CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--#Marinebiotech--Nautilus Biosciences officially opens its expanded facility as Croda's Centre of Innovation for Marine Biotechnology at the UPEI

Generex Biotechnology Announces Record & Payment Dates for 20:1 Stock Dividend

Wed, 31/10/2018 - 14:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s previously announced 20:1 common stock dividend will be Monday, November 5, 2018. The dividend Payment Date will be Tuesday, November 13, 2018. The stock dividend will result in 20 shares of common stock paid on

Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe

Wed, 31/10/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today announced the signing of an amendment to its existing licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate mbH (“medac”), expanding the German pharmaceutical company’s exclusive right to market NATESTO® in the totality of the 28 current EU member countries (including the United Kingdom) as well as Norway, Liechtenstein, Iceland, Turkey (including Turkish Cyp

Pages